Adalimumab (Humira) and Biosimilar Market was valued at USD 20.4 Billion in 2022 and is projected to reach USD 34.4 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030.
As we transition into 2023 and beyond, the outlook for the Adalimumab (Humira) and biosimilars market is expected to continue evolving. One of the key factors influencing demand in the next decade is the increasing pressure on healthcare systems to reduce costs. Biosimilars offer a promising solution, often priced 15-30% lower than their reference biologics, making them a cost-effective alternative. In addition, the growing number of government policies worldwide promoting the use of biosimilars is expected to further boost their uptake. From 2023 to 2033, the global biosimilars market is forecasted to expand significantly, driven by both rising competition and increasing demand for affordable biologics. Regions such as North America and Europe are projected to remain strong markets, while emerging economies in Asia-Pacific and Latin America are anticipated to see accelerated growth as healthcare access improves.
Get an In-Depth Research Analysis of the Global Adalimumab (Humira) and Biosimilar Market Size And Forecast [2025-2032]
The global market for Adalimumab (Humira) and its biosimilars has experienced significant growth and change between 2018 and 2022. Adalimumab, marketed as Humira, is one of the world’s best-selling biologic drugs, primarily used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. With the patent expiration of Humira in 2016, a wave of biosimilars emerged in the market, creating competitive pricing pressures and increasing access to these vital treatments. The period from 2018 to 2022 saw the gradual rise of these biosimilars, which continue to be a driving force in the pharmaceutical industry. Analysts have also pointed out that the market for Humira biosimilars has continued to grow rapidly due to their affordability, availability, and efficiency in treatment. The U.S. market witnessed a significant shift as several biosimilars like Amgen's Amjevita and Boehringer Ingelheim's Cyltezo entered the landscape, challenging Humira's market share.
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Adalimumab (Humira) and Biosimilar Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Adalimumab (Humira) and Biosimilar Market
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Based on Types the Market is categorized into Below types that held the largest Adalimumab (Humira) and Biosimilar market share In 2023.
Syringe
Pen
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Adalimumab (Humira) and Biosimilar Market Research Analysis
1. Introduction of the Global Adalimumab (Humira) and Biosimilar Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Adalimumab (Humira) and Biosimilar Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Adalimumab (Humira) and Biosimilar Market, By Type
6. Global Adalimumab (Humira) and Biosimilar Market, By Application
7. Global Adalimumab (Humira) and Biosimilar Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Adalimumab (Humira) and Biosimilar Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/